Device for in vivo delivery of bioactive agents and method of manufacture thereof

• US 10,398,830 B2
• Filed: 11/19/2001
• Issued: 09/03/2019
• Est. Priority Date: 11/17/2000
• Status: Expired due to Fees

• Current Assignee: Vactronix Scientific, LLC
• Original Assignee: Vactronix Scientific, LLC
• Inventors: Boyle, Christopher T.
• Primary Examiner(s): Woznicki, Jacqueline
• Application Number:
  US10/258,087
• Publication Number:
  US 20040024449A1
• Time in Patent Office: 6,497 Days
• Field of Search: 623 127, 623 139- 148, 623 115- 116
• CPC Class Codes: A61F 2/86 Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2210/0076 multilayered, e.g. laminated structures
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61M 5/14 Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor

Abstract

The present invention consists of an implantable structural element for in vivo delivery of bioactive active agents to a situs in a body. The implantable structural element may be configured as an implantable prosthesis, such as an endoluminal stent, cardiac valve, osteal implant or the like, which serves a dual function of being prosthetic and a carrier for a bioactive agent. Alternatively, the implantable structural element may simply be an implantable article that serves the single function of acting as a time-release carrier for the bioactive agent.

Claims

1. An endoluminal stent for delivering a bioactive agent to a situs in a body comprising:

a radially expandable cylindrical member formed of a plurality of undulating hollow members, each of the plurality of undulating hollow members abutting a portion of an adjacent undulating hollow member and each of the plurality of undulating hollow members being joined to an adjacent undulating hollow member;

a continuous void space formed entirely within at least one of the plurality of undulating hollow members, wherein the continuous void space is bounded by internal wall surfaces of the at least one of a plurality of undulating hollow tubular members, the internal wall surface having a thickness;

a plurality of pores formed in and passing through an external wall surface and internal wall surface thickness of at least one of the plurality of undulating hollow tubular members and communicating between the continuous void space and the external wall surface and being open to an exterior surface of the radially expandable cylindrical element, further wherein each of the pores has a cross section smaller than a smallest cross section of the continuous void space; and

at least one bioactive agent retained within the continuous void space and elutable through the plurality of pores.

2. The endoluminal stent of claim 1, further comprising a plurality of welds connecting portions of the plurality of undulating hollow members.

3. The endoluminal stent according to claim 1, wherein the plurality of undulating hollow members further comprises a material selected from the group consisting of titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, zirconium-titanium-tantalum alloys, nitinol, and stainless steel.

4. The endoluminal stent according to claim 1, wherein the at least one bioactive agent comprises a pharmacologically active agent selected from the group consisting of hydrophobic pharmacologically active agents, hydrophilic pharmacologically active agents, antibiotic drugs, antiviral drugs, neoplastic agents, steroids, fibronectin, anticlotting drugs, anti-platelet function drugs, drugs which prevent smooth muscle cell growth on inner surface wall of vessel, heparin, heparin fragments, aspirin, coumadin, tissue plasminogen activator, urokinase, hirudin, streptokinase, antiproliferatives, antioxidants, antimetabolites, thromboxane inhibitors, non-steroidal and steroidal anti-inflammatory drugs, immunosuppresents, rapamycin, beta and calcium channel blockers, genetic materials including DNA and RNA fragments, complete expression genes, antibodies, lymphokines, growth factors, prostaglandins, leukotrienes, laminin, elastin, collagen, nitric oxide, and integrins.

5. The endoluminal stent according to claim 1, wherein the plurality of undulating hollow members further comprise a vacuum deposited metal.

6. The endoluminal stent of claim 1 wherein, each undulating hollow member includes a first structural region and a second structural region, further wherein the first structural region is subjected to relatively lower stress or strain forces than second structural region upon radial expansion of the radially expandable cylindrical member.